Phaseline

Companies › Recursion Pharmaceuticals

Recursion Pharmaceuticals: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tak-733 (REC-4881)
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 1Familial Adenomatous PolyposisJun 2027
REC-1245–Phase 1UnresectableOct 2028
REC-7735
PIK3CA-H1047R inhibitor
PIK3CAPhase 1Solid TumorsJan 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05552755Tak-733 (REC-4881)Phase 1Familial Adenomatous PolyposisOncologyJun 2027
NCT06678659REC-1245Phase 1UnresectableOncologyOct 2028
NCT07819136REC-7735Phase 1Solid TumorsOncologyJan 2031

From the company's SEC filings

Cash of $550m on 2026-09-30; operating cash outflow about $355m a year; runway about 19 months at that burn, to Apr 2028

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

PIK3CA (1) MAP2K1 (1) MAP2K2 (1)

Companies with the same targets

Roche Eli Lilly Novartis Haihe Biopharma AstraZeneca Pierre Fabre Medicament Shanghai Kechow Pharma Pasithea Therapeutics Merck KGaA SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.